Shilpa Medicare informs about USFDA approval

01 Jan 2019 Evaluate

Shilpa Medicare has informed that the company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) Single Dose Vials. Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum. According to IQVIA MAT Q2 2018 data, the US market for Irinotecan HCL approximately $18 million.

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare Share Price

460.50 6.60 (1.45%)
28-Mar-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.50
Dr. Reddys Lab 6171.85
Cipla 1494.65
Zydus Lifesciences 1013.75
Lupin 1617.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.